Hypoparathyroidism: calcium replacement, monitoring, and the AU GP approach

What hypoparathyroidism is

Hypoparathyroidism is the failure of the parathyroid glands to produce sufficient parathyroid hormone (PTH), resulting in persistent hypocalcaemia and hyperphosphataemia. PTH is the principal regulator of calcium homeostasis: it raises serum calcium by stimulating renal tubular calcium reabsorption, increasing renal phosphate excretion, and activating the renal enzyme that converts calcidiol (25-OH-D) to calcitriol (1,25-OH-D) — the active vitamin D form responsible for intestinal calcium absorption. Without adequate PTH, all three mechanisms fail simultaneously.

In Australia, hypoparathyroidism is most commonly a post-surgical complication. Total thyroidectomy — for Graves’ disease, multinodular goitre, or thyroid cancer — and extensive parathyroid surgery account for the majority of cases. The parathyroid glands are small (3–5 mm), variable in anatomy, and vulnerable to devascularisation or inadvertent excision during neck dissection. Transient post-operative hypocalcaemia is common (up to 30% of total thyroidectomies); permanent hypoparathyroidism — defined as persisting beyond 12 months — occurs in approximately 2–3% of total thyroidectomies in experienced hands but higher in revision or more extensive surgery.

General practitioners encounter this condition in two settings: in the post-operative period following thyroid or parathyroid surgery, where urgent calcium replacement and dose titration are needed; and as ongoing chronic management, coordinating with endocrinology, adjusting calcitriol doses, and monitoring for complications (nephrocalcinosis, nephrolithiasis, cataracts, basal ganglia calcification). NPS MedicineWise and the Endocrine Society of Australia recognise hypoparathyroidism as a condition requiring long-term specialist coordination.

The treatment target is not full normalisation of serum calcium — it is the lowest calcium that keeps patients asymptomatic while limiting hypercalciuria. Understanding this distinction prevents both under-treatment (symptomatic hypocalcaemia) and over-treatment (progressive renal injury from urinary calcium overload).

A. Core clinical — the AU general practice framework

Who to think about

Consider hypoparathyroidism in:

• Any patient with a history of total thyroidectomy, parathyroid surgery, or extended neck dissection
• Any patient presenting with perioral or peripheral paraesthesiae, muscle cramps, carpal or pedal spasm
• Unexpected hypocalcaemia on routine bloods — always calculate corrected calcium (measured Ca + 0.02 × [40 − albumin g/L]) or request laboratory-adjusted reporting
• Family history of hypocalcaemia or unexplained seizures (familial forms)
• DiGeorge syndrome (22q11.2 deletion) — hypoparathyroidism co-occurs with cardiac defects and immune dysfunction

History to take

• Surgical history — thyroid, parathyroid, or neck cancer surgery; timing relative to onset of symptoms
• Symptom pattern — perioral tingling (earliest and most specific), fingertip or toe numbness, muscle cramps, carpopedal spasm, facial twitching
• Functional impact — fatigue, brain fog, anxiety, depressed mood (common and underrecognised in chronic hypoparathyroidism even on treatment)
• Diet — calcium intake, lactose intolerance or dairy avoidance, very-high-phytate diet
• Medications — proton pump inhibitors (reduce calcium carbonate absorption), loop diuretics, bisphosphonates, anticonvulsants, lithium, antifungals (fluconazole, ketoconazole), cinacalcet
• Autoimmune history — type 1 diabetes, Addison’s disease, autoimmune thyroid disease (autoimmune polyglandular syndrome)
• Family history — known hypoparathyroidism, hypocalcaemia, or unexplained seizures in close relatives

Examination

Elicit the clinical signs of hypocalcaemia in any patient with suspected low calcium:

• Trousseau sign — inflate the sphygmomanometer cuff above systolic for 3 minutes; carpal spasm (wrist flexion, metacarpophalangeal flexion, interphalangeal extension) is positive. More sensitive than Chvostek.
• Chvostek sign — gentle percussion 2 cm anterior to the ear over the facial nerve; ipsilateral facial muscle twitch is positive. Less specific; present in up to 25% of normocalcaemic individuals.

Workup

First-line investigations:

Test	Interpretation in hypoparathyroidism
Serum calcium + albumin	Corrected Ca is low; request albumin-adjusted value
Serum PTH	Low or inappropriately normal despite hypocalcaemia
Serum phosphate	Elevated — loss of PTH-mediated phosphaturia
Serum magnesium	Low Mg impairs PTH secretion and action; must exclude and correct
25-OH-D	Assess baseline vitamin D status — MBS item 66833
Creatinine + eGFR	Baseline renal function before starting calcitriol
24-hour urinary calcium	Baseline before treatment to guide ongoing monitoring

MBS items at diagnosis: calcium + albumin (66536), PTH (66629), vitamin D 25-OH (66833).

Differential diagnosis

• Vitamin D deficiency — PTH elevated (secondary hyperparathyroidism), not suppressed; responds to cholecalciferol, not calcitriol alone
• Pseudohypoparathyroidism — PTH elevated (end-organ PTH resistance); Albright hereditary osteodystrophy features (short stature, shortened fourth metacarpal); treated with calcitriol similarly
• Hypomagnesaemia — impairs PTH secretion and peripheral PTH action; calcium normalises only after Mg replacement; common in alcoholism, malabsorption, PPI use
• Hungry bone syndrome — severe hypocalcaemia after parathyroidectomy for primary hyperparathyroidism; high but temporary calcitriol requirements
• Acute pancreatitis, large blood transfusion (citrate chelation) — situational hypocalcaemia

B. Treatment — calcitriol, calcium, and monitoring

Why calcitriol, not plain vitamin D

Calcitriol (1,25-dihydroxyvitamin D) is the active form of vitamin D. Ordinarily, the kidney converts calcidiol (25-OH-D) to calcitriol in a PTH-dependent step. In hypoparathyroidism, PTH is absent — this conversion is impaired regardless of how much cholecalciferol is given. Therapeutic Guidelines and Australian Medicines Handbook both specify calcitriol as the active vitamin D preparation of choice in hypoparathyroidism for this reason.

Alfacalcidol (1-alpha-hydroxyvitamin D) is an alternative — it requires only hepatic hydroxylation to become active. Calcitriol and alfacalcidol are interchangeable at a dose ratio of approximately 2:1 (alfacalcidol 1 mcg ≈ calcitriol 0.5 mcg). Calcitriol is on the PBS general schedule for hypoparathyroidism.

Calcitriol dosing

Starting dose: typically 0.25 mcg twice daily (total 0.5 mcg/day). Titrate upward by 0.25 mcg increments every 4 weeks, guided by corrected serum calcium and 24-hour urinary calcium, until the therapeutic target is reached. Usual maintenance range: 0.5–2.0 mcg/day in divided doses. Doses above 2 mcg/day are unusual and should prompt specialist review.

The short half-life of calcitriol (4–6 hours) means twice-daily dosing maintains more stable serum levels than once-daily administration. Twice-daily is the standard AU schedule; three-times-daily is sometimes used for better stability in difficult-to-control cases.

Elemental calcium supplementation

Calcitriol alone is insufficient without adequate calcium substrate. Target elemental calcium: 500–2000 mg/day in two to three divided doses.

Preparation	Elemental calcium	Notes
Calcium carbonate 1250 mg	500 mg	Preferred; cost-effective; take with food for absorption
Calcium carbonate 600 mg	240 mg	Smaller dose for step-wise titration
Calcium citrate 950 mg	200 mg	Better absorbed without food; preferred with PPI use or achlorhydria

Avoid giving the full daily dose at once — splitting doses and separating from high-phytate foods (bran, legumes), iron supplements, and thyroid hormone improves bioavailability. Use calcium citrate if the patient is on long-term PPI therapy.

Treatment target

The goal is a corrected serum calcium of 2.05–2.20 mmol/L — not full normalisation. This conservative target reduces hypercalciuria, limiting the risk of nephrolithiasis and nephrocalcinosis over years of treatment. The kidneys lack PTH-mediated tubular calcium reabsorption, so even mildly supranormal serum calcium drives significant urinary calcium losses — the principal source of long-term renal morbidity.

Always interpret serum calcium against the albumin-corrected value, or request ionised calcium in patients with abnormal albumin (liver disease, malnutrition, critical illness).

Magnesium: the silent driver

Hypomagnesaemia both impairs PTH secretion and causes peripheral PTH resistance. Check serum magnesium at every presentation and periodically during follow-up. Borderline-low magnesium (0.6–0.7 mmol/L) in a symptomatic patient warrants replacement. Oral magnesium glycinate or citrate 200–400 mg/day (elemental) is better tolerated than magnesium oxide; diarrhoea is the dose-limiting side effect. Intravenous magnesium sulphate is used in the inpatient setting for acute correction.

Monitoring schedule

Parameter	Frequency (stable)	Notes
Corrected Ca + albumin	Every 3–6 months	After any dose change: recheck at 4 weeks
Phosphate	Every 3–6 months	Hyperphosphataemia worsens vascular and soft-tissue calcification
Magnesium	Every 3–6 months	Correct if low before adjusting calcitriol dose
Creatinine + eGFR	Every 3–6 months	Calcitriol causes nephrotoxicity if calcium is over-target
24-hour urinary calcium	Every 3–6 months	Target under 7.5 mmol/day; reduce calcitriol if persistently elevated
25-OH-D	1–2 yearly	Maintain vitamin D replete
Renal ultrasound	Every 5 years	Screen for nephrocalcinosis and calculi — MBS item 55036
Ophthalmology	Every 5 years	Posterior subcapsular cataracts; lenticular calcification

C. Acute hypocalcaemia — the emergency presentation

Acute severe hypocalcaemia — corrected serum calcium below 1.90 mmol/L, or any symptomatic hypocalcaemia with positive Trousseau sign, tetany, laryngospasm, or seizure — is a medical emergency. This most commonly presents in the post-operative period after thyroid surgery, during intercurrent illness (vomiting, diarrhoea, dehydration), or in patients with undertreated or newly recognised hypoparathyroidism.

Recognition

Suspect acute severe hypocalcaemia with:

• Post-thyroidectomy perioral or fingertip tingling (onset typically 24–72 hours post-op)
• Progressive muscle cramps or carpopedal spasm in a patient with known hypoparathyroidism
• Stridor or laryngospasm — the most immediately dangerous complication
• Generalised seizure in a patient without prior epilepsy history
• ECG: prolonged QTc interval (can precipitate ventricular arrhythmia)

Perform the Trousseau sign (cuff inflated above systolic for 3 minutes) in any symptomatic patient — a positive result confirms clinical severity and warrants immediate escalation.

Emergency management

IV calcium gluconate is the agent of choice — calcium chloride is more irritant and carries higher risk of tissue necrosis with extravasation.

Administer 10–20 mL of 10% calcium gluconate (2.25 mmol Ca²⁺ per 10 mL) by slow IV infusion over 10 minutes under cardiac monitoring, for acute tetany or seizure. Follow with a continuous infusion of calcium gluconate in 5% dextrose or normal saline — typically 100 mL of 10% calcium gluconate in 1000 mL at 50–100 mL/hour, titrated to serum calcium every 4–6 hours.

Correct hypomagnesaemia concurrently — calcium levels will not stabilise until magnesium is repleted.

Start or increase oral calcitriol and elemental calcium as soon as the patient can take oral medications, to enable transition off IV calcium.

When to transfer:

Any patient with tetany, laryngospasm, seizure, Trousseau-positive, or corrected Ca below 1.90 mmol/L requires inpatient management with IV calcium. This is not suitable for management in a general practice setting — arrange emergency transfer. Contact the treating surgical team for post-operative presentations, or endocrinology for known hypoparathyroid patients.

Milder presentations (tingling at rest, mild cramps, corrected Ca 1.90–2.05 mmol/L, Trousseau negative) may allow expedited outpatient dose adjustment with re-check within 48–72 hours in a patient who is known, reliable, and close to medical care — but only with documented shared decision-making.

D. Australian operations — MBS, referral, and PTH replacement

MBS item numbers

Relevant MBS items for investigating and monitoring hypoparathyroidism:

• Calcium + albumin: MBS 66536
• PTH: MBS 66629 (clinical justification required: hypocalcaemia or suspected disorder of calcium metabolism)
• Vitamin D (25-OH-D): MBS 66833
• Renal ultrasound: MBS 55036 (abdominal/renal/retroperitoneal ultrasound)

Endocrinologist referral

All newly diagnosed hypoparathyroidism warrants endocrinology involvement to confirm the diagnosis, establish baseline monitoring (including 24-hour urine calcium), advise on calcitriol and calcium strategy, and assess need for genetic testing in non-surgical cases (autosomal dominant hypocalcaemia, DiGeorge syndrome, autoimmune polyglandular syndrome).

Stable, well-controlled patients may be managed primarily in general practice with 6–12 monthly specialist review. The referral letter should include: surgical history, current medications and doses, recent corrected calcium, PTH, phosphate, magnesium, creatinine, vitamin D, and 24-hour urine calcium if available.

The Endocrine Society of Australia maintains a member directory for locating endocrinologists.

PTH replacement

Palopegteriparatide (Yorvipath), a once-daily subcutaneous long-acting PTH analogue, is TGA-approved for chronic hypoparathyroidism in adults who cannot be well controlled on calcitriol and calcium. It is available via the TGA Special Access Scheme (Category B — acknowledges use of an unlisted product) and is not PBS-listed. Cost is approximately AUD $120,000 per year; prescribing is specialist-initiated.

International consensus guidelines (Brandi 2016; Mannstadt 2017; ESE 2025 update) identify candidates as patients with: multiple hospital admissions for acute hypocalcaemia despite optimised conventional therapy; progressive nephrocalcinosis or recurrent nephrolithiasis; persistently elevated urinary calcium refractory to dose reduction; or significant symptom burden unresolved on standard treatment. PTH replacement is not first-line — calcitriol plus elemental calcium remains the cornerstone.

Patient support

Hypopara Australia is the AU consumer advocacy and support organisation for patients with hypoparathyroidism. Refer patients for peer support, education, and access to updated treatment information.

E. Special populations

Pregnancy. Calcitriol requirements typically increase in the second and third trimesters because of foetal calcium demands and placental PTH-related peptide effects. Monitor corrected calcium (or ionised calcium) monthly during pregnancy. Coordinated care between the general practitioner, obstetrician, and endocrinologist is essential — calcitriol requirements often drop sharply post-partum but breastfeeding maintains increased demand. TGA category B3; discuss risks and benefits early.

Children and adolescents. In children, the most important non-surgical causes are DiGeorge syndrome (22q11.2 deletion, presenting neonatally with cardiac defects and immune dysfunction) and autosomal dominant hypocalcaemia from activating calcium-sensing receptor mutations. Management principles are the same, but paediatric endocrinology input is essential for diagnosis and dose titration. Refer to a paediatric endocrinologist promptly for any child with confirmed or suspected hypoparathyroidism.

Older adults. Falls risk is bidirectional: uncorrected hypocalcaemia causes neuromuscular instability; calcitriol over-supplementation causes hypercalciuria and renal calculi. Monitoring compliance tends to decrease with age — regular review, clear patient education, and simplified dosing (twice-daily rather than three-times-daily) improve adherence. Review renal function frequently as eGFR changes alter calcitriol metabolism.

When to escalate

Refer urgently (same day) to the emergency department or endocrinology:

• Corrected serum calcium below 1.90 mmol/L
• Symptomatic hypocalcaemia — positive Trousseau sign, tetany, laryngospasm, generalised seizure, cardiac arrhythmia
• Suspected acute post-thyroidectomy hypocalcaemia

Refer routinely to endocrinology:

• New diagnosis of hypoparathyroidism in any patient
• Persistent difficulty maintaining corrected calcium in target range despite dose adjustments
• Progressive nephrocalcinosis or recurrent nephrolithiasis on monitoring imaging
• Significant unresolved symptoms (fatigue, cognitive impairment, mood disturbance)
• Pregnancy — shared specialist care throughout gestation and post-partum
• Consideration for PTH replacement therapy (palopegteriparatide)

What this article is and is not

This is general health information synthesised from current Australian endocrine guidelines — Therapeutic Guidelines, Australian Medicines Handbook — and international consensus guidelines from the European Society of Endocrinology and peer-reviewed literature on hypoparathyroidism. It is not personal medical advice and does not create a doctor–patient relationship. Individual management — including calcitriol doses, calcium targets, and monitoring intervals — is determined by the treating endocrinologist and general practitioner in the context of each patient’s history, comorbidities, and calcium stability.

For Australian consumer-friendly information: Hypopara Australia, HealthDirect — Hypoparathyroidism, Better Health Channel.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Endocrinology
2. Australian Medicines Handbook
3. Brandi ML et al. — Management of Hypoparathyroidism (J Clin Endocrinol Metab 2016)
4. Mannstadt M et al. — Hypoparathyroidism (Nat Rev Dis Primers 2017)
5. European Society of Endocrinology — Hypoparathyroidism guideline
6. Endocrine Society of Australia
7. TGA
8. NPS MedicineWise
9. HealthDirect — Hypoparathyroidism
10. Better Health Channel — Hypoparathyroidism
11. Hypopara Australia